- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 8th, 2007
Emerging specialty pharmaceutical company Nanotherapeutics will be using its nanoparticle drug delivery technology to develop an HIV oral peptide vaccine after entering into a two year agreement with the National Cancer Institute (NCI).
The Florida-based company will use its proprietary NanoDRY drug delivery technology to develop the peptide vaccine candidate into an oral form which will have targeted delivery to the lower gastrointestinal (GI) tract.
|Related News Press|
Nanoparticles simplify DNA identification and quantification November 27th, 2015
Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015
CEA-Leti to Share Insights into Post-7-nanometer Technologies At Workshop Prior to IEDM in Washington, D.C.: Research Includes CMOS Device Architectures, New Materials and Computing System Paradigms December 1st, 2015